Drugs / LFF571
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01232595 | Oct 2010 → Jul 2013 | Clostridium difficile colitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LFF571 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01232595 ↗ |
| Known as | J3.333.591A | ChEMBL registry synonym — accepted as the source's own label CHEMBL2063705 ↗ |
| Modality | Peptide | “LFF571 is a semisynthetic thiopeptide with potency against C. difficile in vitro.” PMID 25534727 ↗ Dec 2014 |
| Route | Oral | “The systemic exposure following oral administration of 200 mg of LFF571 four times per day for 10 days in patients with C. difficile infection was limited.” PMID 25534724 ↗ Dec 2014 |